

# English Longitudinal Studies of Ageing

<https://www.neurodegenerationresearch.eu/survey/english-longitudinal-studies-of-ageing/>

## **Title of cohort**

English Longitudinal Studies of Ageing

## **Acronym for cohort**

ELSA

## **Name of Principal Investigator - Title**

Prof

## **Name of Principal Investigator - First name**

Andrew

## **Name of Principal Investigator - Last name**

Stephoe

## **Address of institution -Institution**

University College London

## **Address of institution - Street address**

Department of Epidemiology and Public Health, University College London

## **Address of institution - City**

London

## **Address of institution - Postcode**

WC1E 7HB

## **Country**

United Kingdom

## **Website**

<http://www.elsa-project.ac.uk/>

## **Contact email**

[email protected]

## **Funding source**

Department of Health, Department for Work and Pensions, Department for Transport and National Institute on Aging

### **Q1a. Please indicate below if your cohort includes or expects to include, incidence of the following conditions?**

Neurodegenerative disease in general

### **Q1b. When are studies on the above condition(s) expected to become possible?**

Already possible

### **Q2a. In a single sentence what is the stated aim of the cohort?**

Longitudinal multidisciplinary data from a representative sample of the English population aged 50 and older

### **Q2b. What distinguishes this cohort from other population cohorts?**

Focus on ageing

### **Q3a. i) Number of publications that involve use of your cohort to date**

### **Q3a.ii) Please give up to three examples of studies to date (Principal Investigator, Institution, Title of Study)**

Martin Orrell, University College London, Promoting Independence in Dementia| Christina Victor, Brunel University, Loneliness in Later Life| Michelle Miller, University of Warwick, Sleep Disturbances and Mild Cognitive Impairment in the English Longitudinal Study of Ageing

### **Q3b. If data on research outputs are already available please paste the publication list/other data or provide a link to where these data are publicly available**

<http://www.elsa-project.ac.uk/publications>

### **Q3c. If no research has been done as yet, please explain in a few sentences what information (i.e. research findings) you expect will be gained from the population**

### **Q4a. Study criteria: what is the age range of participants at recruitment? Age in years From:**

50

### **Q4a. Study criteria: what is the age range of participants at recruitment? To:**

Until death

### **Q4b. Study criteria: what are the inclusion criteria?**

Age and follow Health Survey for England sampling

**Q4c. Study criteria: what are the exclusion criteria?**

Follow Health Survey for England

**Q5. What is the size of the cohort (i.e. how many participants have enrolled)?**

**Q6a. Please describe what measures are used to characterise participants**

Anthropometric and physical: Blood pressure, grip strength, drug coding, waist and weight measures Balance tests, lung function and height will be dropped from wave 8. Biological: Blood samples Hair and saliva samples dropped in wave 8 Household income Physical health measures Cognitive function measures Psychosocial measures

**Q6b. Are there additional measures for participants with a clinical disorder?**

**Q6c. Are there defined primary and secondary endpoints (e.g. defined health parameters)?**

**If yes please specify**

**Q7. What is the study design (select all that apply)?**

Longitudinal

**Q8. Are your cases matched by**

Age

**Q9a. Does your study include a specialised subset of control participants?**

No

**Q9b. If your study includes a specialised subset of control participants please describe**

**Q10a. i) Please enter the data collection start date**

01/03/2002

**Q10a. ii) Please enter the data collection end date**

**Q10a. iii) Is data collection for this study**

Data collection ongoing| Data analysis ongoing

**Q10b. If data collection is ongoing, are there plans to continue the cohort study beyond the current projected end date?**

**Q11. Is data collected**

**Other please specify here**

**Q12. Is there a system in place to enable re-contact with patients to ask about participation in future studies?**

**Q13a. Please give information on the format and availability of data stored in a database (1)**

Data summarised in database

% available

**Q13a. Please give information on the format and availability of data stored in a database (2)**

Database is web-based

% available

**Q13a. Please give information on the format and availability of data stored in a database (3)**

Database on a spreadsheet

% available

**Q13a. Please give information on the format and availability of data stored in a database (4)**

% available

**Other (please specify)**

% available

**Q13b. Please give information on the format and availability of data held as individual records (1)**

Data is held as individual records

% available

**Q13b. Please give information on the format and availability of data held as individual records (2)**

Data is web-based

% available

**Q13b. Please give information on the format and availability of data held as individual records (3)**

% available

**Q13b. Please give information on the format and availability of data held as individual records (4)**

% available

**Please specify language used**

English

**Q14a. Is data available to other groups?**

Yes

**Q14b. If data is available to other groups what is the access policy/mechanisms for access?**

Local/regional access| National access

**Q15. What data sharing policy is specified as a condition of use?**

Data made publicly available after a specified time point

**Q16a. Are tissues/samples/DNA available to other groups?**

**Q16b i) If yes, please describe below:**

Living donors: DNA

**Q16b. ii) In what form are tissues/samples/DNA supplied?**

Secondary samples: DNA

**Q16b. iii) Is the access policy/mechanism for obtaining samples the same as that for obtaining data (Q14 above)?**

**Q17. Is information on biological characteristics available to other groups?**

No

**Number of Patients**

2500

**% of total cohort**

50

**Types:**

Population Cohorts

**Member States:**

United Kingdom

**Diseases:**

Neurodegenerative disease in general

**Years:**

2016

**Database Categories:**

N/A

**Database Tags:**

N/A